Indivior PLC (INDV) Stock Forecast & Price Target

Indivior PLC has demonstrated significant growth in its key product, Sublocade, with the number of patients treated increasing by approximately 8% year-over-year to around 171,500 in the third quarter of 2025. Furthermore, the company reported a notable rise in prescribers, up about 11%, indicating a broader acceptance and increasing demand for its treatment options, leading to a revised sales guidance for Sublocade of $825M–$845M for the year. The positive outlook is further supported by a 14% sales growth for the product in the same quarter, aligning with Indivior's leadership in medication-assisted treatments (MATs) as public awareness and acceptance of addiction treatment continues to rise.

Indivior's stock outlook is negatively influenced by the anticipated decline in Suboxone revenue due to increasing competition from generic alternatives, which poses a significant risk to overall revenue stability. Although Sublocade is expected to experience growth as it is still in the early stages of commercialization, the company faces challenges as consensus estimates reflect an escalating SG&A expenditure rate that could limit profitability. Additionally, fluctuations in quarterly revenue expectations for Sublocade raise concerns about the sustainability of growth amidst declining revenues from established products.